Clinical research
The failure marks a setback in the hunt for means other than vaccines to provide protection against the novel coronavirus and its variants.
Janssen presented the Phase III Glow study for the elderly with CLL or SLL and the overall survival results from the Phase III MAIA study for patients with NDMM.
Avenue Therpeutics is facing the heat of rejection from FDA once again for its IV non-opioid painkiller tramadol. Here are the reasons behind the rejections
The FDA accepted its pre-Investigational New Drug request for a cell therapy treatment that could be a key factor in controlling HIV.
The study also found the vaccine was 100% effective at preventing moderate and severe disease.
Retinal tissue has been regrown in three patients with age-related macular degeneration with geographic atrophy or dry (atrophic) AMD in a Phase I/IIa study conducted by Lineage Cell Therapeutics.
A busy week for clinical trial news as the ASCO meeting wrapped up and the European Hematology Association 2021 Virtual Congress began. Read on for more.
The 2021 EHA is in full swing. BioSpace is rounding up several presentations from the past two days. Here are some of them.
Beigene presented results from three pivotal trials at the 26th EHA2021 Virtual Congress for the effectiveness of their checkpoint inhibitor tislelizumab in relapsed or refractory lymphoma.
Shares of Vertex fell more than 13% in premarket trading after it announced that it will not advance a novel small molecule corrector of the Z-AAT protein into a Phase III study.
PRESS RELEASES